A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza

ClinicalTrials.gov ID: NCT01050257

Public ClinicalTrials.gov record NCT01050257. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This partially randomized, multi-center parallel-group study will evaluate the safety, pharmacokinetics and the effect on viral load and viral shedding of Tamiflu (Oseltamivir) in patients with influenza. Adult and adolescent patients will be randomized to receive either 100 mg or 200 mg of study drug intravenously every 12 hours. Investigators and patients are blinded to knowledge of the assigned dose of Tamiflu. There is an option to convert to oral Tamiflu after 6 intravenous infusions. The anticipated time on study treatment is 5 days, with an optional treatment extension of a further 5 days, if necessary. There will be a non-randomized, open-label treatment group for patients with moderate/severe renal impairment or renal failure. Intravenous dose levels and frequency will be adjusted appropriately to their renal situation.

Study identification

NCT ID: NCT01050257
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Hoffmann-La Roche; Industry
Enrollment: 118 participants

Conditions and interventions

Conditions

Influenza

Interventions

Oseltamivir IV Drug
Oseltamivir Oral Drug

Drug

Eligibility (public fields only)

Age range: 13 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 31, 2009
Primary completion: Aug 31, 2012
Completion: Aug 31, 2012
Last update posted: Oct 31, 2013

2010 – 2012

United States locations

U.S. sites: 56
U.S. states: 28
U.S. cities: 50

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35233	—
Not listed	Montgomery	Alabama	36106	—
Not listed	Phoenix	Arizona	85008	—
Not listed	Little Rock	Arkansas	72205	—
Not listed	Duarte	California	91010	—
Not listed	Los Angeles	California	90027	—
Not listed	San Diego	California	92120	—
Not listed	Wilmington	Delaware	19803	—
Not listed	Melbourne	Florida	32901	—
Not listed	Miami	Florida	33126	—
Not listed	Pensacola	Florida	32504	—
Not listed	South Miami	Florida	33143	—
Not listed	Tampa	Florida	33606	—
Not listed	Atlanta	Georgia	30309	—
Not listed	Chicago	Illinois	60612	—
Not listed	Chicago	Illinois	60637	—
Not listed	Maywood	Illinois	60153	—
Not listed	Des Moines	Iowa	50314	—
Not listed	Kansas City	Kansas	64128	—
Not listed	Overland Park	Kansas	66211	—
Not listed	Wichita	Kansas	67214	—
Not listed	Madisonville	Kentucky	42431	—
Not listed	New Orleans	Louisiana	70121	—
Not listed	Worcester	Massachusetts	01655	—
Not listed	Detroit	Michigan	48202	—
Not listed	Kalamazoo	Michigan	49007	—
Not listed	Duluth	Minnesota	55805	—
Not listed	Minneapolis	Minnesota	55454	—
Not listed	Jackson	Mississippi	39202	—
Not listed	Saint Joseph	Missouri	64506	—
Not listed	Butte	Montana	59701	—
Not listed	Grand Island	Nebraska	68803	—
Not listed	Holmdel	New Jersey	07733	—
Not listed	New York	New York	10007	—
Not listed	New York	New York	10032	—
Not listed	New York	New York	10065	—
Not listed	South Bronx	New York	10461	—
Not listed	Stony Brook	New York	11794	—
Not listed	The Bronx	New York	10467	—
Not listed	Charlotte	North Carolina	28233	—
Not listed	Winston-Salem	North Carolina	27103	—
Not listed	Akron	Ohio	44304	—
Not listed	Cincinnati	Ohio	45229	—
Not listed	Cincinnati	Ohio	45267	—
Not listed	Cleveland	Ohio	44109	—
Not listed	Dayton	Ohio	45404	—
Not listed	Youngstown	Ohio	44501	—
Not listed	Oklahoma City	Oklahoma	73104	—
Not listed	Philadelphia	Pennsylvania	19106	—
Not listed	Pittsburgh	Pennsylvania	15213-2582	—
Not listed	Dallas	Texas	75216	—
Not listed	Dallas	Texas	75235	—
Not listed	San Antonio	Texas	78205	—
Not listed	San Antonio	Texas	78232	—
Not listed	Norfolk	Virginia	23510	—
Not listed	Charleston	West Virginia	25304	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 40 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01050257, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 31, 2013 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01050257 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →